Tom Bates
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tom Bates has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
- Anne Kathrin Imkampe
Breast Unit, William Harvey Hospital, Ashford, Kent, United Kingdom
4 shared publications M Harrison
4 shared publications- Amtul Razzaq Carmichael
The London Breast Institute, The Princess Grace Hospital, London, UK
3 shared publications M Baum
Department of Surgery, Royal Free and University College, London, UK
3 shared publicationsM. Baum
3 shared publicationsM. Harrison
3 shared publications
Latest Publications
- 1 March 2018
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-12
Single event mitigation for Xilinx 7-series FPGAs
This study establishes the optimal Single Event Upset (SEU) mitigation strategy for Xilinx's 7-Series Field Programmable Gate Arrays (FPGAs). This enables 7-Series FPGAs to be utilised in systems with high exposure to ionising radiation over Xilinx's smaller, radiation-hardened 4-Series and 5-Series FPGAs. The optimal strategy maximises system up-time, with minimal complexity and minimal risk of damaging the target FPGA device. Four SEU mitigation techniques are analysed and compared. Three of these are external scrubbing techniques; blind, readback, and blind with Frame Address Register (FAR) verification; with the fourth being Xilinx's internal scrubber, the Soft Error Mitigation (SEM) Intellectual Property (IP) core. The initial comparisons are quantitative, comparing the four methods for traits that lend themselves to meeting the criteria of the optimal scrubber. The techniques are then compared quantitatively to establish theoretical whole-device scan times for each technique given a range of errors to be corrected. These scan times can be utilised to determine which technique performs the fastest given the error rate and technique parameters. The calculations and resultant data can be computed for every device in the 7-series range. The findings suggest that the optimal solution is to opt not for a traditional mitigation strategy, but for a dynamic mitigation strategy. The fastest scrubber is the SEM IP Core, predominantly due to being internal to the FPGA, and as error rates increase, there becomes a crossover point whereby the blind scrubber with FAR verification comes into play to scrub at higher error rates in a deterministic way. Additionally, it finds that the configuration scrubber can operate at higher frequencies in comparison to NASAs recommendation of scrubbing at an order of magnitude higher than the expected SEU rate. These results provide the optimal scrubber for the 7-Series FPGA, and bring into question the recommendation of scrubbing at a higher order of magnitude than the expected error rate. Additionally, Xilinx's guidance for their FPGAs brings in an essential bit ratio which determines what proportion of the FPGAs is actually being utilised by the design, thereby decreasing the proportion of the errors that impact the design as opposed to empty areas of the FPGA, and hence increasing the speed at which scrubbing can take place with reference to NASAs recommendation.
- 1 March 2018
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-12
Single event mitigation for Xilinx 7-series FPGAs
This study establishes the optimal Single Event Upset (SEU) mitigation strategy for Xilinx's 7-Series Field Programmable Gate Arrays (FPGAs). This enables 7-Series FPGAs to be utilised in systems with high exposure to ionising radiation over Xilinx's smaller, radiation-hardened 4-Series and 5-Series FPGAs. The optimal strategy maximises system up-time, with minimal complexity and minimal risk of damaging the target FPGA device. Four SEU mitigation techniques are analysed and compared. Three of these are external scrubbing techniques; blind, readback, and blind with Frame Address Register (FAR) verification; with the fourth being Xilinx's internal scrubber, the Soft Error Mitigation (SEM) Intellectual Property (IP) core. The initial comparisons are quantitative, comparing the four methods for traits that lend themselves to meeting the criteria of the optimal scrubber. The techniques are then compared quantitatively to establish theoretical whole-device scan times for each technique given a range of errors to be corrected. These scan times can be utilised to determine which technique performs the fastest given the error rate and technique parameters. The calculations and resultant data can be computed for every device in the 7-series range. The findings suggest that the optimal solution is to opt not for a traditional mitigation strategy, but for a dynamic mitigation strategy. The fastest scrubber is the SEM IP Core, predominantly due to being internal to the FPGA, and as error rates increase, there becomes a crossover point whereby the blind scrubber with FAR verification comes into play to scrub at higher error rates in a deterministic way. Additionally, it finds that the configuration scrubber can operate at higher frequencies in comparison to NASAs recommendation of scrubbing at an order of magnitude higher than the expected SEU rate. These results provide the optimal scrubber for the 7-Series FPGA, and bring into question the recommendation of scrubbing at a higher order of magnitude than the expected error rate. Additionally, Xilinx's guidance for their FPGAs brings in an essential bit ratio which determines what proportion of the FPGAs is actually being utilised by the design, thereby decreasing the proportion of the errors that impact the design as opposed to empty areas of the FPGA, and hence increasing the speed at which scrubbing can take place with reference to NASAs recommendation.
- 1 January 2016
- Published by Elsevier in International Journal of Surgery
- Vol. 25, 164
Peer review report 1 on “Do postoperative NSAIDs improve breast cancer outcomes?”
- 1 January 2016
- Published by Elsevier in International Journal of Surgery
- Vol. 25, 164
Peer review report 1 on “Do postoperative NSAIDs improve breast cancer outcomes?”
- Open Access
- 1 January 2015
- Published by Elsevier in International Journal of Surgery
- Vol. 13, S189
Peer review report 1 on “Surgical management of ipsilateral breast tumor recurrence”
- 1 January 2015
- Published by Elsevier in International Journal of Surgery
- Vol. 13, S189
Open AccessPeer review report 1 on “Surgical management of ipsilateral breast tumor recurrence”
- 1 October 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (10) , 1230-1236
A population based study of variations in operation rates for breast cancer, of comorbidity and prognosis at diagnosis: Failure to operate for early breast cancer in older women
- 1 October 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (10) , 1230-1236
A population based study of variations in operation rates for breast cancer, of comorbidity and prognosis at diagnosis: Failure to operate for early breast cancer in older women
- 1 September 2014
- Published by Elsevier in European Journal of Cancer
- Vol. 50 (14) , 2517-2518
Addendum to BASOII Trial report
- 1 September 2014
- Published by Elsevier in European Journal of Cancer
- Vol. 50 (14) , 2517-2518
Addendum to BASOII Trial report
- 1 July 2013
- Published by Elsevier in European Journal of Cancer
- Vol. 49 (10) , 2294-2302
Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial
- 1 July 2013
- Published by Elsevier in European Journal of Cancer
- Vol. 49 (10) , 2294-2302
Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial
- Open Access
- 1 June 2012
- Published by Elsevier in The Breast
- Vol. 21 (3) , 330-335
Primary chemo-radiotherapy in the treatment of locally advanced and inflammatory breast cancer
- 1 June 2012
- Published by Elsevier in The Breast
- Vol. 21 (3) , 330-335
Open AccessPrimary chemo-radiotherapy in the treatment of locally advanced and inflammatory breast cancer
- 8 November 2011
- Published by Hindawi Limited in The Breast Journal
- Vol. 18 (1) , 35-40
Correlation of Age at Oral Contraceptive Pill Start with Age at Breast Cancer Diagnosis
Breast cancer is progressively diagnosed with increasing age. This study aimed to determine whether women who started using the oral contraceptive pill (OCP) at an early age developed breast cancer earlier than women who started using the OCP later in life. A database review of 1,010 breast cancer patients, who had used the OCP at some point in their life, was carried out. Associations of age at OCP start with age at breast cancer diagnosis were determined by multiple linear regression analysis, considering year of birth, year of diagnosis, age at first pregnancy, number of live births, age at menarche, and length of OCP use. There was evidence of a linear trend between age at OCP start and age at breast cancer diagnosis. Women who started using the OCP aged 18 years or younger were, on average, 4 years younger at breast cancer diagnosis than women who started using the OCP over the age of 30 years, and women who started using the OCP aged 22–25 years were, on average, 3 years younger (p-value for trend <0.001). The age when the OCP was started was positively associated with the age when breast cancer was first diagnosed.
- 8 November 2011
- Published by Hindawi Limited in The Breast Journal
- Vol. 18 (1) , 35-40
Correlation of Age at Oral Contraceptive Pill Start with Age at Breast Cancer Diagnosis
Breast cancer is progressively diagnosed with increasing age. This study aimed to determine whether women who started using the oral contraceptive pill (OCP) at an early age developed breast cancer earlier than women who started using the OCP later in life. A database review of 1,010 breast cancer patients, who had used the OCP at some point in their life, was carried out. Associations of age at OCP start with age at breast cancer diagnosis were determined by multiple linear regression analysis, considering year of birth, year of diagnosis, age at first pregnancy, number of live births, age at menarche, and length of OCP use. There was evidence of a linear trend between age at OCP start and age at breast cancer diagnosis. Women who started using the OCP aged 18 years or younger were, on average, 4 years younger at breast cancer diagnosis than women who started using the OCP over the age of 30 years, and women who started using the OCP aged 22–25 years were, on average, 3 years younger (p-value for trend <0.001). The age when the OCP was started was positively associated with the age when breast cancer was first diagnosed.